News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
290,696 Results
Type
Article (15439)
Company Profile (227)
Press Release (275026)
Multimedia
Podcasts (108)
Webinars (12)
Section
Business (90643)
Career Advice (169)
Deals (13466)
Drug Delivery (47)
Drug Development (50941)
Employer Resources (31)
FDA (5952)
Job Trends (5201)
News (145668)
Policy (10095)
Tag
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (4)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (958)
Accelerated approval (32)
ADA (33)
Adcomms (15)
Allergies (118)
Alliances (21773)
ALS (177)
Alzheimer's disease (1202)
Antibody-drug conjugate (ADC) (447)
Approvals (6286)
Artificial intelligence (401)
ASCO (221)
Autoimmune disease (301)
Automation (16)
Bankruptcy (107)
Best Places to Work (4558)
BIO (54)
BIOSECURE Act (6)
Biosimilars (138)
BioSpace Insights (69)
Biotechnology (176)
Bladder cancer (127)
Brain cancer (59)
Breast cancer (449)
Cancer (4305)
Cardiovascular disease (320)
Career advice (159)
Career pathing (12)
CAR-T (299)
CDC (8)
Celiac Disease (1)
Cell therapy (783)
Cervical cancer (25)
Clinical research (45476)
Collaboration (1567)
Commercialization (3)
Company closure (3)
Compensation (834)
Complete response letters (66)
COVID-19 (1132)
CRISPR (114)
C-suite (867)
Cystic fibrosis (122)
Data (6234)
Denatured (23)
Depression (125)
Dermatology (72)
Diabetes (355)
Diagnostics (1498)
Digital health (19)
Diversity (6)
Diversity, equity & inclusion (9)
Drug discovery (305)
Drug pricing (54)
Drug shortages (3)
Duchenne muscular dystrophy (304)
Earnings (32969)
Editorial (35)
Employer branding (4)
Employer resources (29)
Events (53980)
Executive appointments (740)
FDA (8358)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (23)
Frontotemporal dementia (32)
Funding (1298)
Gene editing (237)
Generative AI (39)
Gene therapy (639)
GLP-1 (584)
Government (1192)
Grass and pollen (3)
Guidances (180)
Healthcare (6743)
Hematology (118)
HIV (31)
Huntington's disease (61)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (101)
Immunology and inflammation (258)
Immuno-oncology (87)
Indications (151)
Infectious disease (1294)
Inflammatory bowel disease (188)
Inflation Reduction Act (10)
Influenza (60)
Intellectual property (227)
Interviews (20)
IPO (7392)
IRA (13)
Job creations (872)
Job search strategy (133)
JPM (41)
Kidney cancer (11)
Labor market (35)
Layoffs (264)
Leadership (15)
Legal (1406)
Licensing (5)
Liver cancer (48)
Longevity (25)
Lung cancer (572)
Lymphoma (332)
Machine learning (35)
Management (7)
Manufacturing (581)
Marketing (9)
MASH (169)
Medical affairs (1)
Medical device (2729)
Medtech (2764)
Mergers & acquisitions (6870)
Metabolic disorders (979)
mRNA (177)
Multiple sclerosis (133)
NASH (14)
Neurodegenerative disease (372)
Neuropsychiatric disorders (88)
Neuroscience (2488)
Neurotech (1)
NextGen: Class of 2026 (2039)
Non-profit (885)
Now hiring (42)
Obesity (434)
Opinion (146)
Ovarian cancer (199)
Pain (144)
Pancreatic cancer (256)
Parkinson's disease (324)
Partnered (13)
Patents (430)
Patient recruitment (608)
Peanut (51)
People (27476)
Pharmaceutical (29)
Pharmacy benefit managers (6)
Phase 1 (16116)
Phase 2 (21152)
Phase 3 (13345)
Pipeline (6767)
Policy (108)
Postmarket research (854)
Preclinical (6810)
Press Release (30)
Prostate cancer (216)
Psychedelics (70)
Radiopharmaceuticals (299)
Rare diseases (973)
Real estate (1460)
Recruiting (12)
Regulatory (10897)
Reports (20)
Research institute (994)
Resumes & cover letters (20)
Rett syndrome (40)
RNA editing (30)
RSV (24)
Schizophrenia (154)
Series A (254)
Series B (177)
Service/supplier (1)
Sickle cell disease (98)
Special edition (20)
Spinal muscular atrophy (126)
Sponsored (17)
Startups (2036)
State (1)
Stomach cancer (5)
Supply chain (41)
Tariffs (19)
The Weekly (83)
Vaccines (421)
Venture capital (95)
Weight loss (232)
Women's health (50)
Worklife (2)
Date
Today (89)
Last 7 days (331)
Last 30 days (1225)
Last 365 days (18115)
2026 (10789)
2025 (18094)
2024 (20475)
2023 (22412)
2022 (26812)
2021 (27814)
2020 (23367)
2019 (16233)
2018 (11743)
2017 (13750)
2016 (11853)
2015 (14351)
2014 (10396)
2013 (7489)
2012 (7550)
2011 (7616)
2010 (7430)
Location
Africa (156)
Alabama (78)
Alaska (2)
Arizona (91)
Arkansas (6)
Asia (18875)
Australia (3239)
California (9043)
Canada (2296)
China (1126)
Colorado (322)
Connecticut (338)
Delaware (313)
Europe (40566)
Florida (1188)
Georgia (263)
Hawaii (3)
Idaho (18)
Illinois (556)
India (53)
Indiana (218)
Iowa (8)
Japan (337)
Kansas (87)
Kentucky (11)
Louisiana (17)
Maine (14)
Maryland (929)
Massachusetts (7230)
Michigan (128)
Minnesota (320)
Mississippi (3)
Missouri (38)
Montana (17)
Nebraska (6)
Nevada (48)
New Hampshire (22)
New Jersey (2055)
New Mexico (13)
New York (2255)
North Carolina (1057)
North Dakota (7)
Northern California (4612)
Ohio (226)
Oklahoma (11)
Oregon (25)
Pennsylvania (1659)
Puerto Rico (12)
Rhode Island (26)
South America (216)
South Carolina (13)
Southern California (3653)
Tennessee (59)
Texas (1246)
United States (29947)
Utah (125)
Virginia (183)
Washington D.C. (37)
Washington State (741)
West Virginia (1)
Wisconsin (64)
290,696 Results for "kyn therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia
October 1, 2025
·
3 min read
Press Releases
Cognision Announces Partnership with Kynexis to Utilize its COGNISION® System in a Phase 2 Trial of KYN-5356 in Subjects with Schizophrenia
November 17, 2025
·
3 min read
Drug Development
Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
Kynexis announced today that the first healthy volunteers have been dosed in its first-in-human phase 1 study of KYN-5356. KYN-5356, a clinical-stage small molecule targeting a key enzyme in the kynurenine pathway known as KAT-II, is being developed for cognitive impairment associated with schizophrenia (CIAS).
January 4, 2024
·
1 min read
Press Releases
Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
December 18, 2024
·
3 min read
Press Releases
Kyntra Bio to Report First Quarter 2026 Financial Results
May 4, 2026
·
1 min read
Press Releases
United Therapeutics Corporation Acquires Thymmune Therapeutics
July 2, 2026
·
4 min read
Press Releases
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
July 21, 2026
·
7 min read
Layoffs
ADC Therapeutics lays off staff after 27 patient deaths mar Zynlonta readout
After 27 deaths were reported in a group receiving its blood cancer drug, ADC Therapeutics is downsizing, implementing layoffs for about 30 workers.
June 24, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
·
1 min read
Series B
City Therapeutics builds RNAi pipeline with $99.5M series B
City Therapeutics, one of
BioSpace
’s NextGen companies for 2026, was started by RNA royalty John Maraganore, former CEO of Alnylam.
June 8, 2026
·
2 min read
·
Tristan Manalac
1 of 29,070
Next
